Alnylam Pharmaceuticals Inc (ALNY)vsCureVac NV (CVAC)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
CVAC
CureVac NV
$4.66
0.00%
HEALTHCARE · Cap: $1.05B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 5960% more annual revenue ($4.29B vs $70.74M). CVAC leads profitability with a 182.1% profit margin vs 12.6%. CVAC trades at a lower P/E of 7.0x. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
CVAC
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+64.3%
Fair Value
$13.04
Current Price
$4.66
$8.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 182 of every $100 in revenue as profit
Strong operational efficiency at 573.0%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Smaller company, higher risk/reward
Revenue declined 89.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CVAC
The strongest argument for CVAC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 182.1% and operating margin at 573.0%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : CVAC
The primary concerns for CVAC are Market Cap, Revenue Growth.
Key Dynamics to Monitor
ALNY profiles as a growth stock while CVAC is a declining play — different risk/reward profiles.
CVAC carries more volatility with a beta of 1.84 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 56/100) and 96.4% revenue growth. CVAC offers better value entry with a 64.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
CureVac NV
HEALTHCARE · BIOTECHNOLOGY · USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?